FDA Clarification on Food Establishment Waiver from Requirements of the Sanitary Transportation of Human and Animal Food Rule
标准简介
Clarification on Food Establishment Waiver from Requirements of the Sanitary Transportation of Human and Animal Food Rule[附网盘链接]是FDA于之前发布的FDA标准,适用于美国。标准截图
![Clarification on Food Establishment Waiver from Requirements of the Sanitary Transportation of Human and Animal Food Rule[附网盘链接]](/img/2021091410361726tjf.jpg)
标准文档说明
标准文档类型为Clarification on Food Establishment Waiver from Requirements of the Sanitary Transportation of Human and Animal Food Rule[附网盘链接]高清PDF版本(文字版),标准文档内可进行搜索,可以复制原文,可粘贴。标准部分原文
Clarification on Food Establishment Waiver from Requirements of the Sanitary Transportation of Human and Animal Food Rule: Guidance for 1
Industry This guidance represents the current thinking of the Food and Drug Administration (FDA, that Agency, or we) on this topic. It does not establish any rights for any person and is not binding on FDA or the public. You can use an alternative approach if it satisfies the requirements of the applicable statutes and regulations. To discuss an alternative approach, contact the FDA staff responsible for this guidance as listed on the title page. I. Introduction This guidance is intended for those persons who are subject to the Sanitary Transportation of Human and Animal Food Rule (81 FR 20091), published on April 6, 2016. Specifically, this guidance provides clarification on the scope of the waiver for food establishments that provide food directly to consumers from the requirements of the Sanitary Transportation of Human and Animal Food Rule (the food establishment waiver) in response to questions the Agency has received since publication of the final rule. FDA's guidance documents, including this guidance, do not establish legally enforceable responsibilities. Instead, guidances describe our current thinking on a topic and should be viewed only as recommendations, unless specific regulatory or statutory requirements are cited. The use of the word should in FDA guidances means that something is suggested or recommended, but not required. 1
This guidance has been prepared by the Office of Food Safety in the Center for Food Safety and Applied Nutrition. 3
网盘链接
百度网盘:https://pan.baidu.com/s/1U_RQofOfpZjMLEnRX1em_Q
提取码:nyi4
【温馨提示】大资料ISO是提供信息发布的专业信息类网站,所有内容均由用户发布,不代表本站观点,本站亦不存储所涉及的文件及资料。如有【免费资料】以及【付费资料】,请用户根据自己的需求,自行判断是否需要获取。如有交易诈骗、内容侵权可发送邮件至kf@dzl100.com,我们审查后若发现情况属实,会立即对相关内容进行删除处理。
加载用时:26.8148 毫秒
相关评论
相关文章
-
FDA Clinical Pharmacology Labeling for Human Prescription Drug and Biological Products — Content and Format
Clinical Pharmacology Labeling for Human Prescription Drug and Biological Products — Content and Format[附网盘链接]是Food And Drug Administration于当前发布的FDA标准,适用于United States。本次分享的标准文档为高清PDF(文字版),标准文档内可搜索,可复制,可粘贴。本文结尾附网盘链接。
-
FDA Deviation Reporting for Human Cells, Tissues, and Cellular and Tissue-Based Products Regulated Solely Under Section 361 of the Public Health Service Act and 21 CFR Part 1271
Deviation Reporting for Human Cells, Tissues, and Cellular and Tissue-Based Products Regulated Solely Under Section 361 of the Public Health Service Act and 21 CFR Part 1271[附网盘链接]是FDA于过去发布的FDA标准,适用于US。本次分享的标准文档为高清PDF(文字版),标准文档内可搜索,可复制,可粘贴。本文结尾附网盘链接。
-
FDA 30-Day Notices, 135-Day Premarket Approval (PMA) Supplements and 75-Day Humanitarian Device Exemption (HDE) Supplements for Manufacturing Method or Process Changes
30-Day Notices, 135-Day Premarket Approval (PMA) Supplements and 75-Day Humanitarian Device Exemption (HDE) Supplements for Manufacturing Method or Process Changes[附网盘链接]是Food And Drug Administration于之前发布的FDA标准,适用于U.S。本次分享的标准文档为高清PDF(文字版),标准文档内可搜索,可复制,可粘贴。本文结尾附网盘链接。
-
FDA Expansion Cohorts Use in First-In-Human Clinical Trials to Expedite Development of Oncology Drugs and Biologics
Expansion Cohorts Use in First-In-Human Clinical Trials to Expedite Development of Oncology Drugs and Biologics[附网盘链接]是Food&Drug Administration于过去发布的FDA标准,适用于US。本次分享的标准文档为高清PDF(文字版),标准文档内可搜索,可复制,可粘贴。本文结尾附网盘链接。
-
FDA Drug Abuse and Dependence Section of Labeling for Human Prescription Drug and Biological Products — Content and Format
Drug Abuse and Dependence Section of Labeling for Human Prescription Drug and Biological Products — Content and Format[附网盘链接]是Food And Drug Administration于不久前发布的FDA标准,适用于U.S。本次分享的标准文档为高清PDF(文字版),标准文档内可搜索,可复制,可粘贴。本文结尾附网盘链接。
-
FDA Expanded Access to Investigational Drugs for Treatment Use - Questions and Answers
Expanded Access to Investigational Drugs for Treatment Use - Questions and Answers[附网盘链接]是Food&Drug Administration于不久前发布的FDA标准,适用于U.S。本次分享的标准文档为高清PDF(文字版),标准文档内可搜索,可复制,可粘贴。本文结尾附网盘链接。
-
FDA Exculpatory Language in Informed Consent
Exculpatory Language in Informed Consent[附网盘链接]是FDA于不久前发布的FDA标准,适用于美国。本次分享的标准文档为高清PDF(文字版),标准文档内可搜索,可复制,可粘贴。本文结尾附网盘链接。
-
FDA Allowable Excess Volume and Labeled Vial Fill Size in Injectable Drug and Biological Products
Allowable Excess Volume and Labeled Vial Fill Size in Injectable Drug and Biological Products[附网盘链接]是Food And Drug Administration于不久之前发布的FDA标准,适用于US。本次分享的标准文档为高清PDF(文字版),标准文档内可搜索,可复制,可粘贴。本文结尾附网盘链接。
-
FDA Adverse Accreditation Decisions, SuspensionRevocation of Certificates, or Patient and Physician Notification Orders Draft
Adverse Accreditation Decisions, SuspensionRevocation of Certificates, or Patient and Physician Notification Orders Draft[附网盘链接]是Food And Drug Administration于不久之前发布的FDA标准,适用于United States。本次分享的标准文档为高清PDF(文字版),标准文档内可搜索,可复制,可粘贴。本文结尾附网盘链接。
-
CVM GFI #185 (VICH GL43) Target Animal Safety for Veterinary Pharmaceutical Products.pdf[网盘链接]
GFI #185 (VICH GL43) Target Animal Safety for Veterinary Pharmaceutical Products.pdf是于发布的标准,适用于。本次分享的标准文档为高清PDF(文字版),标准文档内可搜索,可复制,可粘贴。本文结尾附网盘链接。
-
FDA Dissolution Testing and Acceptance Criteria for Immediate-Release Solid Oral Dosage Form Drug Products Containing High Solubility Drug Substances
Dissolution Testing and Acceptance Criteria for Immediate-Release Solid Oral Dosage Form Drug Products Containing High Solubility Drug Substances[附网盘链接]是FDA于过去发布的FDA标准,适用于美国。本次分享的标准文档为高清PDF(文字版),标准文档内可搜索,可复制,可粘贴。本文结尾附网盘链接。
-
FDA Adaptive Design Clinical Trials for Drugs and Biologics Guidance for Industry
Adaptive Design Clinical Trials for Drugs and Biologics Guidance for Industry[附网盘链接]是FDA于过去发布的FDA标准,适用于美国。本次分享的标准文档为高清PDF(文字版),标准文档内可搜索,可复制,可粘贴。本文结尾附网盘链接。
-
FDA Assay Migration Studies for In Vitro Diagnostic Devices Guidance for Industry and FDA Staff
Assay Migration Studies for In Vitro Diagnostic Devices Guidance for Industry and FDA Staff[附网盘链接]是FDA于过去发布的FDA标准,适用于United States。本次分享的标准文档为高清PDF(文字版),标准文档内可搜索,可复制,可粘贴。本文结尾附网盘链接。
-
FDA Clinical Pharmacology Labeling for Human Prescription Drug and Biological Products — Content and Format
Clinical Pharmacology Labeling for Human Prescription Drug and Biological Products — Content and Format[附网盘链接]是Food And Drug Administration于当前发布的FDA标准,适用于United States。本次分享的标准文档为高清PDF(文字版),标准文档内可搜索,可复制,可粘贴。本文结尾附网盘链接。
-
FDA Chronic Hepatitis D Virus Infection Developing Drugs for Treatment Guidance for Industry
Chronic Hepatitis D Virus Infection Developing Drugs for Treatment Guidance for Industry[附网盘链接]是Food&Drug Administration于当前发布的FDA标准,适用于United States。本次分享的标准文档为高清PDF(文字版),标准文档内可搜索,可复制,可粘贴。本文结尾附网盘链接。